SD Biosensor Inc (137310) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SD Biosensor Inc (137310) has a cash flow conversion efficiency ratio of 0.001x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.55 Billion ≈ $1.05 Million USD) by net assets (₩2.41 Trillion ≈ $1.63 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SD Biosensor Inc market cap and net worth for the company's overall valuation and market capitalisation.
SD Biosensor Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how SD Biosensor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SD Biosensor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SD Biosensor Inc ranked by their cash flow conversion efficiency. Explore 137310 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dymatic Chemicals Inc
SHE:002054
|
0.019x |
|
Transcoal Pacific Tbk PT
JK:TCPI
|
0.080x |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
0.091x |
|
Nagarro SE
XETRA:NA9
|
0.166x |
|
PTC India Limited
NSE:PTC
|
0.317x |
|
Greenlight Capital Re Ltd
NASDAQ:GLRE
|
0.045x |
|
Nueva Expresión Textil S.A.
MC:NXT
|
-0.017x |
|
Concord International Securities Co Ltd
TWO:5864
|
-0.119x |
Annual Cash Flow Conversion Efficiency for SD Biosensor Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of SD Biosensor Inc from 2019 to 2025. View current stock price of SD Biosensor Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩2.34 Trillion ≈ $1.58 Billion |
₩357.52 Billion ≈ $242.28 Million |
0.153x | +186.60% |
| 2024-12-31 | ₩2.93 Trillion ≈ $1.99 Billion |
₩156.53 Billion ≈ $106.08 Million |
0.053x | +162.38% |
| 2023-12-31 | ₩2.83 Trillion ≈ $1.92 Billion |
₩-242.32 Billion ≈ $-164.22 Million |
-0.086x | -128.33% |
| 2022-12-31 | ₩2.95 Trillion ≈ $2.00 Billion |
₩890.23 Billion ≈ $603.30 Million |
0.302x | -46.10% |
| 2021-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
₩1.23 Trillion ≈ $836.90 Million |
0.560x | -14.29% |
| 2020-12-31 | ₩757.55 Billion ≈ $513.38 Million |
₩495.38 Billion ≈ $335.71 Million |
0.654x | +5650.64% |
| 2019-12-31 | ₩137.91 Billion ≈ $93.46 Million |
₩-1.62 Billion ≈ $-1.10 Million |
-0.012x | -- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more